Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder that lacks a disease-modifying therapy. Leucine-rich repeat kinase 2 (LRRK2) was implicated as the most common genetic cause of PD. We previously established a LRRK2-G2019S Drosophila model that displayed the crucial phenotypes of LRRK2 parkinsonism. Here, we used a two-step approach to identify compounds from the FDA-approved licensed drug library that could suppress neurite degeneration in LRRK2-G2019S parkinsonism. Of 640 compounds, 29 rescued neurite degeneration phenotypes and 3 restored motor disability and dopaminergic neuron loss in aged LRRK2-G2019S flies. Of these three drugs, lovastatin had the highest lipophilicity, which facilitated crossing the blood–brain barrier. In LRRK2-G2019S knock-in mice and stably transfected human dopaminergic cells, lovastatin significantly rescued neurite degeneration in a dose-dependent manner, within a range of 0.05–0.1 μm. The beneficial effect of lovastatin was exerted by activating anti-apoptotic Akt/Nrf signaling and decreasing caspase 3 levels. We also observed that lovastatin inhibited GSK3β activity, a kinase downstream of Akt, by up-regulating GSK3β (Ser9) phosphorylation. This inhibition subsequently decreased tau phosphorylation, which was linked to neuronal cytoskeleton instability. Conversely, pre-treatment with the Akt inhibitor, A6730, blocked the lovastatin-induced neuroprotective effect. The rescuing effects of lovastatin in dendritic arborization of LRRK2-G2019S neurons were abolished by co-expressing either a mutant allele of Akt (Akt104226) or a constitutively active form of GSK3β (sggS9A). Our findings demonstrated that lovastatin restored LRRK2-G2019S neurite degeneration by augmenting Akt/NRF2 pathway and inhibiting downstream GSK3β activity, which decreased phospho-tau levels. We suggested that lovastatin is a potential disease-modifying agent for LRRK2-G2019S parkinsonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · cited 1×
“cells, requiring phosphorylation by kinases such as Akt to inactivate its activity (27).”
BackgroundRamonet, D., Daher, J. P. L., Lin, B. M., Stafa, K., Kim, J., Banerjee, R., Westerlund, M., Pletnikova, O., Glauser, L., Yang, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018568 · Cited by 405 · cited 2×
“Those reports indicated that abnormal neurite morphology, namely a reduction in neurite length and complexity, was a disease-related phenotype of LRRK2 parkinsonism (15,16).”
BackgroundAmyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinson’s Disease
Martin, I., Kim, J. W., Lee, B. D., Kang, H. C., Xu, J.-C., Jia, H., Stankowski, J., Kim, M.-S., Zhong, J., Kumar, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.064 · Cited by 265 · cited 1×
“Several studies have shown that overexpression of LRRK2-G2019S, with aberrantly elevated kinase activity, results in shortened neurites in either in vitro primary neuronal culture (12,16,30,31) or in vivo dentate gyrus granule cells (15).”
BackgroundMalagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228 · cited 1×
“has been observed in post-mortem PD brains (21), and defective Akt signaling was associated with a loss of dopaminergic neurons (22).”
BackgroundGSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205 · cited 1×
“GSK3β is an upstream kinase that phosphorylates tau; moreover, GSK3βwas reported to be associated with PD (36).”
Background
Cited by
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
A synaptic perspective of fragile X syndrome and autism spectrum Disorders.
Bagni, C., & Zukin, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.041 · Cited by 326
“Interestingly, GSK3β activity is down-modulated by lovastatin (Lin et al., 2016), a statin drug used for lowering cholesterol which has also an effect in inhibiting the Ras-ERK1/2 signaling pathway, exaggerated in FXS (Berry-Kravis et al., 2015; Caku et al., 2014; Osterweil et al., 2010).”
BackgroundLi, J., Ma, S., Chen, J., Hu, K., Li, Y., Zhang, Z., Su, Z., Woodgett, J. R., Li, M., & Huang, Q. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00081 · Cited by 76
“Both GSK-3α and GSK-3β Are Activated During Parkinsonian Dopaminergic Neurodegeneration Dephosphorylation of GSK-3β at Ser9, a marker indicating activation of GSK-3β, was widely observed in various PD models in vitro and in vivo (Nagao and Hayashi, 2009; Wang et al., 2013; Lin et al., 2016; Chen et al., 2017).”
BackgroundRegulation of Small GTPase Prenylation in the Nervous System
Reddy, J. M., Raut, N. G. R., Seifert, J. L., & Hynds, D. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01870-0 · Cited by 23
Metadata
- Authors
- Lin, C.-H., Lin, H.-I., Chen, M.-L., Lai, T.-T., Cao, L.-P., Farrer, M. J., Wu, R.-M., & Chien, C.-T.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-02-29
- Volume
- 25
- Issue
- 10
- Pages
- 1965-1978
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2326804423
- Cited by
- 55
- References
- 6
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity. https://app.cochat.ai/papers/10.1093/hmg/ddw068
- The paper
- Lin, C.-H., Lin, H.-I., Chen, M.-L., Lai, T.-T., Cao, L.-P., Farrer, M. J., Wu, R.-M., & Chien, C.-T. (2016). Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddw068
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.